Characterization CYP1A2, CYP2C9, CYP2C19 and CYP2D6 Polymorphisms Using HRMA in Psychiatry Patients with Schizophrenia and Bipolar Disease for Personalized Medicine.

Yenilmez E., Tamam L., Karaytug O., TULİ A.

Combinatorial chemistry & high throughput screening, cilt.21, sa.5, ss.374-380, 2018 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 21 Sayı: 5
  • Basım Tarihi: 2018
  • Doi Numarası: 10.2174/1386207321666180619164726
  • Dergi Adı: Combinatorial chemistry & high throughput screening
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.374-380
  • Anahtar Kelimeler: CYP450 polymorphism, pharmacogenetic, HRMA, schizophrenia, bipolar disease, drug dosage adjustment, DRUG-METABOLIZING-ENZYMES, GENETIC-POLYMORPHISM, CLINICAL-IMPLICATIONS, GENOTYPE FREQUENCIES, AFRICAN POPULATION, CYTOCHROME P4502C9, PHARMACOGENETICS, DIVERSITY, THERAPY, IDENTIFICATION
  • Çukurova Üniversitesi Adresli: Evet

Özet

Background: The interindividual genetic variations in drug metabolizing enzymes effects the impact and toxicity in plenty of drugs.